Ask VialBase
other

Ventfort

Also known as: Vesartulin, vascular bioregulator, vessel peptide bioregulator
Anecdotal evidence FDA: not-FDA-approved WADA: Not listed

Ventfort is a vascular "Cytomax" in the Khavinson bioregulator family — a natural polypeptide complex extracted from the blood-vessel wall / endothelial tissue of young animals, marketed to support endothelial repair, microcirculation and vessel elasticity. Unlike its synthetic counterpart Vesugen (the KED tripeptide), no Ventfort-specific study is indexed in PubMed — its proposed mechanism is inferred from the broader short-peptide bioregulator class. It is not FDA-approved. For educational purposes only. Not medical advice. Ventfort is presented as a Cytomax — a natural organ-extract polypeptide complex, not a defined synthetic peptide. The logic of the Khavinson family is that a young

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight Not defined — natural polypeptide complex (Cytomax), not a single molecule
Half-life Not characterized no
CAS number —
Route Subcutaneous · Oral subcutaneous preferred
02

Mechanism

Ventfort is marketed as a vascular "Cytomax" in the Khavinson bioregulator family — a natural polypeptide complex extracted from the blood-vessel wall / endothelial tissue of young animals (cattle), not a defined synthetic peptide. Like the rest of the Cytomax/Cytogen family it is proposed to act by epigenetic, organ-targeted bioregulation: reintroducing the regulatory peptide signals of young vascular tissue to nudge endothelial gene expression back toward a more youthful pattern, supporting endothelial repair, microcirculation and vessel elasticity. Important: there is NO Ventfort-specific peer-reviewed study indexed in PubMed. The mechanism is inferred from the broader Khavinson short-peptide bioregulator class and from its synthetic vascular sibling Vesugen (the KED tripeptide); Ventfort's own composition is documented only in manufacturer/vendor literature.

03

Dosing

DOSE RANGE 10–20 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, repeated 2–4×/year

Traditional Khavinson-style pulsed cycles taken from practitioner/vendor protocols, not from a controlled dosing study. No Ventfort-specific pharmacokinetic or dose-finding research exists. Oral and subcutaneous routes are both described in vendor material; the classic Cytomax extract form is often capsule/oral.

04

Stacking & interactions

Layered vascular bioregulation (natural Cytomax complex + synthetic KED Cytogen, same organ target)

Vascular + connective-tissue repair and angiogenesis support

Broad vascular/tissue healing and angiogenesis

Cardiovascular-longevity protocol (vascular bioregulator + pineal/telomere peptide)

05

Sourcing

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Lipid Panel
DURING CYCLE
  • Lipid Panel
POST-CYCLE
  • CMP
  • Lipid Panel
Safety & Regulatory Status
FDA STATUS not-FDA-approved
WADA STATUS Not listed

Regulatory status for Ventfort may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Ventfort?
Ventfort is a vascular "Cytomax" in the Khavinson bioregulator family — a natural polypeptide complex extracted from the blood-vessel wall and endothelial tissue of young animals, rather than a single synthetic peptide. It is marketed to support endothelial repair, microcirculation and vessel elasticity and to counter age-related vascular stiffness. It is the organ-extract counterpart to the synthetic vascular peptide Vesugen (KED).
Is there real research on Ventfort?
This is the honest part: there is no Ventfort-specific study indexed in PubMed — searching "Ventfort" returns zero records, with no clinical trial, animal study, or named in vitro paper. Its vascular claims are extrapolated from (1) the broader Khavinson short-peptide bioregulator class and (2) its synthetic vascular sibling Vesugen (the KED tripeptide), whose vasoprotective effects are themselves only in-vitro and largely Russian-language. Treat Ventfort's specific claims as unproven.
What is Ventfort's peptide sequence?
Ventfort does not have a single defined amino-acid sequence. As a Cytomax it is a natural mixture of peptides purified from vascular tissue, not one molecule. This is the key difference from its synthetic Cytogen counterpart Vesugen, which is the defined tripeptide Lys-Glu-Asp (KED, ~390 Da). No peer-reviewed sequence or molecular-weight characterization of Ventfort exists.
How is Ventfort different from Vesugen?
They target the same organ — the vascular wall — but differ in origin. Ventfort is a natural organ-extract complex (Cytomax) with no single sequence; Vesugen is a lab-synthesized tripeptide (Lys-Glu-Asp / KED) with a known sequence. The bioregulator tradition pairs a Cytomax with its same-organ Cytogen. Vesugen at least has named in-vitro vascular studies; Ventfort has none of its own, so its evidence base is thinner.
How is Ventfort dosed?
Practitioner and vendor protocols use short pulsed courses of about 10–20 mg per cycle for 10–20 days, repeated two to four times a year, orally or subcutaneously. These are traditional Khavinson-style regimens, not trial-validated doses — no Ventfort-specific dosing study exists, and there is no standardized reconstitution protocol for this line.
Is Ventfort FDA-approved?
No. Ventfort is not FDA-approved and is sold only as a research compound. It is used within Russian bioregulatory/cardiovascular practice and is not prohibited by WADA. Because there is no compound-specific data and the core peptide-DNA mechanism is scientifically controversial, anyone with cardiovascular disease should be managed by a physician rather than self-treating with an unproven peptide.